Navigation Links
IDM Pharma to Present at BIO InvestorForum in San Francisco
Date:10/4/2007

and the EMEA, and the Company's goal of making L-MTP-PE available to patients as quickly as possible. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, the possibility that the Company may not be able to collect, analyze and submit additional data in an amendment to the NDA for L-MTP-PE by the first quarter of 2008, if at all, the possibility that such data will not support the benefit of L-MTP-PE in the treatment of non-metastatic osteosarcoma, will not allow a more robust analysis of L-MTP-PE, will not continue to support its overall survival benefit in osteosarcoma, and may not provide substantial evidence for the potential regulatory approval of L-MTP-PE, the timing of the FDA's and EMEA's review of the submissions for marketing approval of L-MTP-PE, the ability of the Company to respond to questions raised by the FDA and EMEA in a satisfactory manner, the time needed to respond to any issues raised by the FDA and EMEA with regard to regulatory submissions for L-MTP-PE, the possibility that regulatory authorities may not consider preclinical and early clinical development work conducted by Ciba-Geigy and efficacy data from the Phase 3 trial conducted by Children's Oncology Group as adequate for their assessment of L-MTP-PE, which may cause delays in review, may result in the regulatory authorities requiring the Company to conduct additional clinical trials, or may result in a determination by the regulatory authorities that the data does not support marketing approval, whether regulatory authorities will approve L-MTP-PE within the time frame expected by the Company or at all, and whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved by regulatory authorities. Other risks affecting the Company and its drug development programs include whether the Company or any of its collaborators will be able to develop pharmaceutical products
'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... PHILADELPHIA , Nov. 26, 2014 ... environments. Human exploration of space requires astronauts to maintain ... safety and success, and prevent potential errors and accidents. ... little is known about how cognition is affected by ... affected. Now, Penn Medicine researchers are poised ...
(Date:11/26/2014)... The ETC (Emerging Technology Centers) ... centers, announced today that applications for AccelerateBaltimore™ (AB) ... “Do you have a big idea?,” asked ETC’s ... know about it. AccelerateBaltimore helps you and your ... just 13 weeks.” Interested game changers with ...
(Date:11/26/2014)... 2014 SonaCare Medical, a leading ... devices, recently participated in the American Urology Association’s ... .” Key opinion leaders in urology presented on ... small renal masses while attendees had the opportunity ... in hands-on labs. Attendees at the Los Angeles, ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 The Pittcon ... its official conference and exposition mobile app, ... free download in the App Store for iOS and ... valuable resource tool before, during and after the event. ... details on exhibiting companies, technical sessions, Conferee Networking sessions ...
Breaking Biology Technology:Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Pittcon Releases 2015 Mobile App 2
... First Milestone, NEW YORK, May 13 NeoStem, ... collection, processing and long-term,storage of adult stem cells for ... secured for a new stem cell collection center in ... MD MBA, NeoStem,s Chairman and Chief Executive Officer,commented: "Securing ...
... call scheduled today at 8:00 a.m. Pacific Time, ... ) today announced its financial results for the first ... 2008, the Company posted,total revenues of $17.0 million and ... of revenue earned in the quarter that was,attributable to ...
... responsible for coordinating nanotechnology research and regulations across the ... University to craft a white paper that will lay ... risks associated with nanotechnology to the media and the ... been negotiating this project for nearly 18 months. , ...
Cached Biology Technology:NeoStem to Expand Stem Cell Collection Center Network to Florida 2NeoStem to Expand Stem Cell Collection Center Network to Florida 3SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 2SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 3SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 4SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 5SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 6SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 7SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 8Federal government taps NC State experts to explain nanotech risks 2
(Date:11/7/2014)... Auguste, associate professor, biomedical engineering, in the Grove ... New York, have identified a molecule that could ... most aggressive forms of breast cancer. , Triple ... rate owing to aggressive proliferation and metastasis and ... Auguste,s team, discovered the overexpression of intercellular adhesion ...
(Date:11/7/2014)... November 6, 2014 Leading Biometric companies ... mobile security revolutionizing online transactions.  Companies in focus today are: ... (NYSE: BABA ), Google Inc. (NASDAQ: ... Inc. (NASDAQ: EBAY ) and MasterCard Inc. (NYSE: ... and NXTDW), a biometric authentication company focused on the growing ...
(Date:11/6/2014)... of metastasis, yet progress in preventing and treating ... been particularly challenging to design drugs that work ... systems biology at Harvard Medical School. , ... already metastasized." , Gujral and colleagues have now ... better understand how metastasis begins. Their findings may ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Migration negation 2Migration negation 3
... Researchers from the University of North Carolina at Chapel ... million to study the many ways cocaine use during ... infants. The project,s researchers hope their findings will ... both mothers and children, and prove valuable to others ...
... Energy and Environmental Policy Research have produced a report ... are under consideration in the United States as a ... of the three-part study found that, based on an ... U.S. programs for other emissions, such a program can ...
... Cerveny arrived in coastal southeast Alaska in 1999, she ... the natural environment. She soon found, however, that women ... and making sense of the changes that were taking ... on the fly, ultimately conducting more than 200 hour-long ...
Cached Biology News:UNC, Yale partner to study effects of cocaine use on mother-infant relationships 2MIT analysis shows how cap-and-trade plans can cut greenhouse emissions 2Balance between traditional activities, tourism key to sustaining coastal Alaska communities 2
Component in MasterPure™ Purification Kits...
... (X/R) Red System consists of concentrated ... and X/R Red Buffer. The X/R ... to produce red staining that may ... , Buffer, 100 mL , Chromogen, ...
... Signets FAST RED Chromogen System ... and substrate buffer. FAST RED ... alkaline phosphatase to produce red ... The FAST ...
Mouse Cell Line Slides...
Biology Products: